Lundbeck Depression Drug To Return To India Market With Warning Label
This article was originally published in PharmAsia News
India's health ministry is allowing Lundbeck's Deanxit (flupenthixol/malitracen) depression drug to return to the market where it is to be sold by Mankind Pharma, ending a year-long suspension.
You may also be interested in...
Non-profit approach is reassuring for healthcare payers, but vaccines won’t be ready to stop pandemic at its peak.
Executives On The Move: BMS Taps Barclays Exec For Strategy Spot, Epizyme Selects Science Chief And A Board Election At ADC Therapeutics
Bristol-Myers Squibb taps Barclays chair of global life sciences as it EVP, strategy and business development, and cancer therapeutics firm Epizyme Inc. selects a chief scientific officer. At ADC Therapeutics, an oncology drug development company, a new chairman is elected.